| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | 人乳寡糖用于在患有非乳糜泻小麦和/或麸质敏感性患者中治疗症状 | CN202080041415.7 | 2020-06-04 | CN113939301A | 2022-01-14 | B·麦康奈尔; L·K·比格斯奈斯 |
| 本发明涉及人乳寡糖(HMO)、包括HMO的合成组合物用于在非乳糜泻小麦和/或麸质敏感性患者中预防性地降低症状严重性和/或发生率、以及用于在患者中降低非胃肠道症状的严重性和/或发生率，以及其方法。 | ||||||
| 42 | 包含含有不可水解共价键的聚合物结合剂的药物组合物及其在治疗乳糜泻中的用途 | CN201210260973.X | 2006-10-27 | CN102784165A | 2012-11-21 | 让-克里斯托弗·勒鲁; 穆罕默德·纳塞尔·埃丁 |
| 本发明涉及一种包含聚合物结合剂和药学可接受载体的药物组合物，所述聚合物结合剂包含具有由不可水解的共价键构成的主链的高分子量合成聚合物，所述聚合物能在pH低于谷蛋白和源自谷蛋白降解的肽的等电点时形成静电键，并且能在胃肠道中与谷蛋白或源自谷蛋白降解的肽结合。本发明还涉及使用所述聚合物结合剂用于结合谷蛋白或源自谷蛋白降解的肽、用于减少谷蛋白降解成毒性肽或用于减少谷蛋白或源自谷蛋白降解的肽与胃肠道粘膜的相互作用的方法。 | ||||||
| 43 | 包含含有不可水解共价键的聚合物结合剂的药物组合物及其在治疗乳糜泻中的用途 | CN200680050656.8 | 2006-10-27 | CN101360505A | 2009-02-04 | 让-克里斯托弗·勒鲁; 穆罕默德·纳塞尔·埃丁 |
| 本发明涉及一种包含聚合物结合剂和药学可接受载体的药物组合物，所述聚合物结合剂包含具有由不可水解的共价键构成的主链的高分子量合成聚合物，所述聚合物能在pH低于谷蛋白和源自谷蛋白降解的肽的等电点时形成静电键，并且能在胃肠道中与谷蛋白或源自谷蛋白降解的肽结合。本发明还涉及使用所述聚合物结合剂用于结合谷蛋白或源自谷蛋白降解的肽、用于减少谷蛋白降解成毒性肽或用于减少谷蛋白或源自谷蛋白降解的肽与胃肠道粘膜的相互作用的方法。 | ||||||
| 44 | 包含含有不可水解共价键的聚合物结合剂的药物组合物及其在治疗乳糜泻中的用途 | CN200680050656.8 | 2006-10-27 | CN101360505B | 2015-09-09 | 让-克里斯托弗·勒鲁; 穆罕默德·纳塞尔·埃丁 |
| 本发明涉及一种包含聚合物结合剂和药学可接受载体的药物组合物，所述聚合物结合剂包含具有由不可水解的共价键构成的主链的高分子量合成聚合物，所述聚合物能在pH低于谷蛋白和源自谷蛋白降解的肽的等电点时形成静电键，并且能在胃肠道中与谷蛋白或源自谷蛋白降解的肽结合。本发明还涉及使用所述聚合物结合剂用于结合谷蛋白或源自谷蛋白降解的肽、用于减少谷蛋白降解成毒性肽或用于减少谷蛋白或源自谷蛋白降解的肽与胃肠道粘膜的相互作用的方法。 | ||||||
| 45 | 包含含有不可水解共价键的聚合物结合剂的药物组合物及其在治疗乳糜泻中的用途 | CN201210260973.X | 2006-10-27 | CN102784165B | 2015-02-25 | 让-克里斯托弗·勒鲁; 穆罕默德·纳塞尔·埃丁 |
| 本发明涉及一种包含聚合物结合剂和药学可接受载体的药物组合物，所述聚合物结合剂包含具有由不可水解的共价键构成的主链的高分子量合成聚合物，所述聚合物能在pH低于谷蛋白和源自谷蛋白降解的肽的等电点时形成静电键，并且能在胃肠道中与谷蛋白或源自谷蛋白降解的肽结合。本发明还涉及使用所述聚合物结合剂用于结合谷蛋白或源自谷蛋白降解的肽、用于减少谷蛋白降解成毒性肽或用于减少谷蛋白或源自谷蛋白降解的肽与胃肠道粘膜的相互作用的方法。 | ||||||
| 46 | ABDOMINALE BIFURKATIONSPROTHESE | EP13722719.5 | 2013-05-03 | EP2846733B1 | 2016-08-31 | BARTHOLD, Franz-Peter; WÖRNE, Christian |
| 47 | ABDOMINAL WOUND DRESSING | EP01925755.9 | 2001-05-09 | EP1284777A1 | 2003-02-26 | HUNT, Kenneth, William; HEATON, Keith, Patrick; SCHROEDER, Wayne |
| A system and method for the temporary closure of a wound, especially an abdominal wound, to facilitate re-entry, final closure, and long term healing of the wound. An abdominal wound dressing and methods of use are described that enable the application of negative pressure to the wound site in a site healing promoting manner while also limiting the formation of adhesions that would prevent the removal of the dressing. The dressing comprises a layer of porous foam material (36) enclosed by sheets of elastomeric material (38) punctuated by a number of appropriately placed holes (34). Multiple layers of porous foam may also be used. A suction tube connector (16) is provided on an upper surface of a layer of foam (12) for connection to a negative pressure source. At least one layer of foam is enclosed in elastomeric material and is placed in direct contact with the tissue within the open wound. Fluids are drawn by negative pressure through the holes positioned in the elastomeric envelope, and through the foam. If multiple foam layers are employed, the lower layer(s) of foam are of a finer porosity while the upper layer of foam is coarse. An adhesive elastomeric sheet (14) covers the entire wound dressing and seals the edges to the skin surrounding the wound. An appropriate vacuum device is attached to the suction tube connector. | ||||||
| 48 | Celiac antigen | US09263331 | 1999-03-05 | US06653085B1 | 2003-11-25 | Amin Tjota |
| In this invention a novel antigen and a novel antibody-antigen complex are provided for screening patients suspected of having celiac disease. The antigen is prepared by starting with human placenta tissue which is perfused with a hepes and collagenase buffer to obtain a single cell suspension. This suspension is enriched to obtain an enriched protein portion and then separated out to obtain an embryonic celiac antigen (ECA). This ECA is used with serum from patients to effect binding of ECA with IgA in the serum while applying a human IgA antibody to the serum. The results are then read on a spectrophotometer to confirm or negate the presence of celiac disease. | ||||||
| 49 | Celiac antigen | US626243 | 1996-03-29 | US5716794A | 1998-02-10 | Amin Tjota |
| In this invention a novel antigen is provided for screening patients suspected of having celiac disease. The antigen is prepared by starting with human placenta tissue which is perfused with a herpes and collagenase buffer to obtain a signle cell suspension. This suspension is enriched to obtain an enriched protein portion and then separated out to obtain an embryonic celiac antigen (ECA). This ECA is used with serum from patients to effect binding of ECA with IgA in the serum while applying a human IgA antibody to the serum. The results are then read on a spectrophotometer to confirm or negate the presence of celiac disease. | ||||||
| 50 | セリアック病に使用するためのＩｇＹ組成物 | JP2014531275 | 2012-09-26 | JP2014534170A | 2014-12-18 | カール・スクリナー |
| 本発明は、配列番号1のアミノ酸配列を有するペプチドに特異的に結合するIgY抗体、その断片、および/またはFab断片を含有することを特徴とするIgY組成物、ならびにセリアック病、リウマチ、および/または小麦アレルギーの治療におけるこのIgY組成物の使用に関する。 | ||||||
| 51 | Amidase from variovorax | US10309294 | 2002-12-04 | US20030186423A1 | 2003-10-02 | Stefan Verseck; Karlheinz Drauz; Andreas Bommarius; Maria-Regina Kula; Lutz Krieg; Heike Slusarczyk; Marion Ansorge-Schumacher |
| The present invention relates to an amidase enzyme, nucleic acids encoding the amidase, as well as methods of employing the nucleic acids and/or amidase to produce, for example, enantiomericallyenriched compounds such as D-amino acids. | ||||||
| 52 | A METHOD FOR TREATING CELIAC DISEASE | EP01947784.3 | 2001-06-15 | EP1305012A2 | 2003-05-02 | CAVAZZA, Claudio; MOSCONI, Luigi |
| A method for treating celiac disease comprising administration of a composition containing an alkanoyl L-carnitine wherein the alkanoyl group is straight or branched and has 2-6 carbon atoms and the pharmacologically acceptable salts thereof. | ||||||
| 53 | 셀리악병 진단용 프라이머 세트와 이를 이용한 셀리악병 진단방법 | KR1020140172453 | 2014-12-03 | KR101736744B1 | 2017-05-17 | 김우태; 이혜영; 장성민; 박병주 |
| 본발명은글루텐(gluten) 성분에민감한셀리악병(celiac disease) 진단용프라이머세트와이를이용한셀리악병진단방법에관한것으로, 셀리악병과관련된 HLA-DQ2(DQA1*0501/0505, DQB1*0201/0202), HLA-DQ8(DQA1*0301/DQB1*0302) 및 DR4(DRB1*04)에존재하는대립유전자(allele)를 PCR-SSP 기법을사용하여글루텐성분에민감한셀리악병을진단하는것을특징으로한다. 따라서, 기존의검사법인알러지피부검사, 혈청학적특이면역검사및 점막조직검사에비해민감도와특이도가높고, 검체로부터짧은시간내에간편하고신속하게 DNA를검출할수 있다는장점이있다. | ||||||
| 54 | Treatment of celiac disease with IgA | US13214952 | 2011-08-22 | US08709413B2 | 2014-04-29 | Michael R. Simon |
| A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally. | ||||||
| 55 | Treatment of celiac disease with IgA | US13013648 | 2011-01-25 | US08119104B2 | 2012-02-21 | Michael Richard Simon; Mark Andrew Kroenke |
| A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. | ||||||
| 56 | Diagnostic method for celiac sprue | US13289905 | 2011-11-04 | US08426145B2 | 2013-04-23 | Chaitan Khosla; Lu Shan |
| Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | ||||||
| 57 | Treatment of celiac disease with IgA | US13214952 | 2011-08-22 | US20110305753A1 | 2011-12-15 | Michael R. Simon |
| A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally. | ||||||
| 58 | Diagnostic method for celiac sprue | US12839278 | 2010-07-19 | US08071316B2 | 2011-12-06 | Chaitan Khosla; Lu Shan |
| Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. | ||||||
| 59 | Markers for the diagnosis of celiac disease | US13499678 | 2010-10-01 | US09221881B2 | 2015-12-29 | Karl Skriner |
| The invention relates to new peptides and to their use in the diagnosis of celiac disease. | ||||||
| 60 | METHODS OF TREATING CELIAC DISEASE | EP13797188.3 | 2013-05-30 | EP2854839A1 | 2015-04-08 | FALLON, Joan.M.; HEIL, Matthew.F.; SZIGETHY, James.; FALLON, James.J. |
| Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder. | ||||||
QQ群二维码
意见反馈
意见反馈